Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

387239

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the cost to his Department has been of prescribing anti-depressant drugs in each year since 2010; and what estimate he has made of such costs in the next financial year.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	5402
answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>Information on the cost of prescribing antidepressant medicines is provided in the table below. Projected costs are not available.</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="4"><p>Cost of antidepressant drugs, as classified in British National Formulary section 4.3, <em>Antidepressant drugs</em>, in England: 2010 to 2014 <sup>1</sup></p></td></tr><tr><td><p>Total drugs</p></td><td colspan="3"><p>Cost (£ million)</p></td></tr><tr><td><p> </p></td><td><p>Primary care <sup>2</sup></p></td><td><p>Secondary care <sup>3 </sup></p></td><td><p>Total <sup>4</sup></p></td></tr><tr><td><p>2010</p></td><td><p>220,372.8</p></td><td><p>8,221.6</p></td><td><p>228,594.4</p></td></tr><tr><td><p>2011</p></td><td><p>270,177.2</p></td><td><p>7,818.5</p></td><td><p>277,995.7</p></td></tr><tr><td><p>2012</p></td><td><p>211,145.4</p></td><td><p>7,453.5</p></td><td><p>218,598.9</p></td></tr><tr><td><p>2013</p></td><td><p>282,121.6</p></td><td><p>8,708.3</p></td><td><p>290,829.9</p></td></tr><tr><td><p>2014</p></td><td><p>265,003.7</p></td><td><p>9,021.7</p></td><td><p>274,025.4</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Source:</em> Prescription Cost Analysis and IMS HEALTH: Hospital Pharmacy Audit, provided by the Health and Social Care Information Centre</p><p> </p><p> </p><p> </p><p><em>Notes: </em></p><p> </p><ol start="1" type="1"><li>Differences in annual national totals will, in part, be due to changes in the reimbursement price of some (mainly generic) antidepressant drugs.</li><li>Primary care net ingredient cost is the basic cost of a drug. It does not take account of discounts, dispensing costs, fees or prescription charges income.</li><li>Secondary care cost of medicine at National Health Service list price and will not necessarily be the price the hospital paid.</li><li>Total figures may not sum due to rounding.</li></ol><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 08/07/2015 15:52:54 answering member 1201 label Biography information for Alistair Burt
tabling member	545 label Biography information for Paul Flynn

387240

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Antidepressants
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much each clinical commissioning group spent on anti-depressant prescription drugs in the financial year 2014-15.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	5403
answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>Available data for the total net ingredient cost of prescription items written in each clinical commissioning group, in England, and dispensed in the community, in the United Kingdom, for antidepressant medicines, as defined by the British National Formulary, section 4.3, <em>Antidepressant drugs</em>, for the 2014-15 year, is attached.</p><p> </p><p> </p><p> </p><p>The data has been extracted from the Prescribing Analysis and Cost Tool system and provided by the Health and Social Care Information Centre.</p><p> </p> answering member constituency North East Bedfordshire answering member printed Alistair Burt question first answered 08/07/2015 15:56:35 answering member 1201 label Biography information for Alistair Burt attachment 1 file name BNF Antidepressant drugs spreadsheet.xlsx title Antidepressant drugs spend per CCG 2014-15
tabling member	545 label Biography information for Paul Flynn

387241

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prescription Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to (a) tackle addiction to and (b) reduce deaths caused by prescription drugs.
tabling member constituency	Newport West
tabling member printed	Paul Flynn
uin	5401
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>The UK Guidelines on the Clinical Management of Drug Misuse and Dependence are currently being updated by an expert group which is being supported by Public Health England (PHE). Addiction to prescription and over-the-counter medicines is among the areas being looked at. The updated guidance is due to be published in 2016.</p><p> </p><p> </p><p> </p><p>PHE provides support to local authorities to carry out a joint strategic needs assessment (JSNA) in their local area each year. A key part of this support is the annual JSNA support pack, which includes data on addiction to medicines, which can help commissioners assess local problems with prescription drug addiction and commission appropriate services. In addition, PHE is supporting a small number of local areas to pilot improvements in their commissioning of responses to additions to medicines.</p><p> </p><p> </p><p> </p><p>PHE is also supporting an expert group led by the Faculty of Pain Medicine at the Royal College of Anaesthetists to develop a core resource on opioid pain medicines that can be used as a source of consistent information by any medical body developing its own materials.</p><p> </p><p> </p><p> </p><p>In September 2013 the Home Secretary commissioned the Advisory Council on the Misuse of Drugs (ACMD) to explore the potential for medical and social harms arising from the diversion and illicit supply of prescription drugs. This work includes consideration of the prevalence of misuse, user demographics, and the most common drugs being misused. The ACMD’s report on its findings is expected later this year.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/07/2015 13:59:28 answering member 3918 label Biography information for Jane Ellison
tabling member	545 label Biography information for Paul Flynn

387244

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent representations he has received on possible links between quality of care, operational productivity and safe staffing levels from (a) Lord Carter, (b) Robert Francis and (c) others.
tabling member constituency	Denton and Reddish
tabling member printed	Andrew Gwynne
uin	5413
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>The Secretary of State for Health has received no correspondence or other written representations from Lord Carter on the possible links between quality of care, operational productivity and safe staffing levels. The Secretary of State met Lord Carter on 13 May 2015 and 18 May 2015 to discuss procurement. The Parliamentary Under-Secretary of State for NHS Productivity (Lord Prior) met with Lord Carter on 8 June 2015 and 1 July 2015 and had a telephone call with him on 21 May. In each case it was to receive an update on the work on improving operational productivity that Lord Carter is doing on behalf of the Department. I also met with Lord Carter very briefly on 29 June 2015 to discuss the work. On 11 June 2015 Lord Carter published his Interim report, <em><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/434202/carter-interim-report.pdf" target="_blank">Review of Operational Productivity in NHS providers</a></em>.</p><p> </p><p> </p><p> </p><p>The Secretary of State has received no correspondence or other written representations from Sir Robert Francis QC on the possible links between quality of care, operational productivity and safe staffing levels. The Secretary of State met Robert Francis on 19 January 2015 to discuss the <em><a href="https://freedomtospeakup.org.uk/wp-content/uploads/2014/07/F2SU_web.pdf" target="_blank">Freedom to Speak Up report</a></em> and on 9 February 2015 when the report was formally handed over.</p><p> </p><p> </p><p> </p><p>The Secretary of State and other Ministers regularly meet healthcare leaders and receive correspondence and other written representations on a wide range of issues, including safe staffing.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/07/2015 15:25:24 answering member 4020 label Biography information for George Freeman
tabling member	1506 label Biography information for Andrew Gwynne

387252

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	NHS England: Disclosure of Information
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will publish the minutes of the meetings of (a) NHS England's Clinical Priorities Group which met on 25 and 26 June 2015 and (b) the Specialised Services Commissioning Committee which met on 30 June 2015.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	5456
answer	answer is ministerial correction date of answer 07/07/2015 answer text <p>NHS England has advised that there was no meeting of the Clinical Priorities Advisory Group (CPAG) on the 25 and 26 June. The minutes of the CPAG meeting on 15 and 16 June and the minutes of the Specialised Commissioning Committee of 30 June will be published on NHS England’s website in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/07/2015 16:16:53 answering member 4020 label Biography information for George Freeman
tabling member	1540 label Biography information for Greg Mulholland

387253

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when NHS England will publish its methodology for ranking treatments to commission for ultra-rare diseases.
tabling member constituency	Leeds North West
tabling member printed	Greg Mulholland
uin	5417
answer	answer is ministerial correction date of answer 07/07/2015 answer text <p>NHS England published its Prioritisation Framework for 2015/16 on 26 June 2015. A copy has been attached and it is also available on the NHS England website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf" target="_blank">http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/nhse-respns-publictn-17-06-15.pdf</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 07/07/2015 13:22:10 answering member 4020 label Biography information for George Freeman attachment 1 file name Prioritisation Framework.pdf title NHS England Prioritisation Framework 2015/16
tabling member	1540 label Biography information for Greg Mulholland

387272

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the National Institute for Health and Care Excellence to commence work on the development of clinical guidance for pancreatic cancer.
tabling member constituency	Newbury
tabling member printed	Richard Benyon
uin	5356
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) has advised that it expects to commence work on the development of a clinical guideline on pancreatic cancer in late Autumn 2015. The provisional schedule for development of this guideline will be made available on NICE’s website: <a href="http://www.nice.org.uk/" target="_blank">www.nice.org.uk</a> in due course.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/07/2015 15:28:00 answering member 4020 label Biography information for George Freeman
tabling member	1547 label Biography information for Lord Benyon

387273

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that all pancreatic cancer patients have access to dietetic treatment, advice and support; and if he will make a statement.
tabling member constituency	Newbury
tabling member printed	Richard Benyon
uin	5351
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>NHS England has a published a service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>The service specification sets out that all patients with upper gastrointestinal disease (including pancreatic cancer) are at risk of dietary problems and should have access to full dietetic inpatient and outpatient services. Dieticians should be available to see patients during regular outpatient clinics and be available for consultation on ward rounds and multidisciplinary team meetings.</p><p> </p><p> </p><p> </p><p>The full service specification can be found at:</p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2013/06/a02-cncr-panc.pdf" target="_blank">http://www.england.nhs.uk/wp-content/uploads/2013/06/a02-cncr-panc.pdf</a></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/07/2015 15:08:34 answering member 3918 label Biography information for Jane Ellison
tabling member	1547 label Biography information for Lord Benyon

387274

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure new treatment options for pancreatic cancer are made available on the NHS at the earliest opportunity; and if he will make a statement.
tabling member constituency	Newbury
tabling member printed	Richard Benyon
uin	5379
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>In commissioning cancer services, NHS England is supported by clinical reference groups (CRGs) which are responsible for developing strategies, pathways and service specifications for each group of cancer type, including a Hepatobiliary and Pancreatic CRG which covers pancreatic cancer. CRGs consider the latest evidence available.</p><p> </p><p> </p><p> </p><p>We take the issue of ensuring rapid access to innovative therapies very seriously, which is why we have launched an Accelerated Access Review to make recommendations to Government later in the year on speeding up access for National Health Service patients to innovative and cost effective new medicines, diagnostics and medical technologies.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 09/07/2015 14:16:15 answering member 3918 label Biography information for Jane Ellison
tabling member	1547 label Biography information for Lord Benyon

387275

registered interest
date	02/07/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answer of 3 December 2014 to Question 216468, what progress he has made in establishing trials for pancreatic cancer patients using stereotactic ablative radiotherapy.
tabling member constituency	Newbury
tabling member printed	Richard Benyon
uin	5489
answer	answer is ministerial correction date of answer 09/07/2015 answer text <p>Cancer Research UK is funding the SPARC trial, which is led by the University of Oxford. This is a phase I trial of pre-operative, margin intensive, stereotactic body radiation therapy for previously untreated borderline resectable pancreatic cancer. The National Institute for Health Research (NIHR) Clinical Research Network is providing research infrastructure for the trial.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/07/2015 14:37:34 answering member 4020 label Biography information for George Freeman
tabling member	1547 label Biography information for Lord Benyon